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Biobanks can have a pivotal role in elucidating disease etiology, translation, and advancing public health. However, meeting
these challenges hinges on a critical shift in the way science is conducted and requires biobank harmonization. There is
growing recognition that a common strategy is imperative to develop biobanking globally and effectively. To help guide this
strategy, we articulate key principles, goals, and priorities underpinning a roadmap for global biobanking to accelerate health
science, patient care, and public health. The need to manage and share very large amounts of data has driven innovations on
many fronts. Although technological solutions are allowing biobanks to reach new levels of integration, increasingly powerful
data-collection tools, analytical techniques, and the results they generate raise new ethical and legal issues and challenges,
necessitating a reconsideration of previous policies, practices, and ethical norms. These manifold advances and the investments
that support them are also fueling opportunities for biobanks to ultimately become integral parts of health-care systems in
many countries. International harmonization to increase interoperability and sustainability are two strategic priorities for
biobanking. Tackling these issues requires an environment favorably inclined toward scientific funding and equipped to address
socio-ethical challenges. Cooperation and collaboration must extend beyond systems to enable the exchange of data and
samples to strategic alliances between many organizations, including governmental bodies, funding agencies, public and
private science enterprises, and other stakeholders, including patients. A common vision is required and we articulate the
essential basis of such a vision herein.
European Journal of Human Genetics (2012) 20, 1105–1111; doi:10.1038/ejhg.2012.96; published online 20 June 2012
Health-care systems worldwide are severely strained by the exponen-
tial growth of aging populations and the rising incidence of common
chronic diseases. We face these public health challenges in a scientific
era characterized by the emergence of novel technologies and tools
that can improve the diagnosis, prevention, treatment and manage-
ment of disease, and accelerate advances in personalized medicine.
Realizing the potential of these technologies relies heavily on access to
comprehensive and well-organized collections of human biological
samples and associated clinical and research data. These collections,
referred to as biobanks, provide the essential raw materials that fuel
the contemporary advance of biotechnology, scientific and medical
research, and improvements in both public health1 and individual
patient care. The purpose of this white paper is to articulate a vision
for global biobanking that calls for enhanced sharing and pooling of
data from our biobanks to accelerate health research and translation.
Biobanking is not a new concept or field. Biospecimens have been
collected and stored in conjunction with clinical and epidemiological
studies for several decades. The principal departures from long-standing
epidemiological tradition and past biobanking efforts include the
number and size of the initiatives now underway and the emphasis on
obtaining biological material together with a rich array of phenotypic
information. The phenotypes being collected may include diagnoses,
risk factors, physical and metabolic parameters (such as blood pre-
ssure and insulin resistance), other clinically relevant data, as well as
data on behavioral and social factors. The availability of whole-
genome technologies has significantly expanded the number of
questions that can be addressed from the analysis of these collections.
There has also been a substantial change in the national and inter-
national context for biobanking. In particular, modern biobanks are
now recognized as important infrastructural platforms for specimen
and data sharing, and not just as tools for single studies. This means
that biobanks have to be designed, constructed, funded and managed
with flexibility, sustainability, and international interoperability. More-
over, because of the rapid developments in science and technology,
1Department of Genes and Environment, Division of Epidemiology, The Norwegian Institute of Public Health, Oslo, Norway; 2University of Leicester, Leicester, UK; 3Public
Population Project in Genomics (P3G), Montreal, QC, Canada; 4Centre of Genomics and Policy, McGill University, Montreal, QC, Canada; 5SDIX Inc., Newark, NJ, USA;
6Lindpaintner Biobanks Consulting, Muttenz, Switzerland; 7The US Department of Veterans Affairs, Washington, DC, USA; 8Center of Genetic Medicine, Northwestern University
Medical School, Chicago, IL, USA; 9Biotherapeutics and Bioinnovation Center Pfizer Inc, South San Francisco, CA, USA; 10Research Institute – McGill University Health Centre,
Montreal, QC, Canada; 11International Prevention Research Institute, Lyon, France; 12European, Middle Eastern and African Society for Biopreservation and Biobanking (ESBB),
Marseille, France; 13Centre for Health, Law and Emerging Technologies, Department of Public Health, University of Oxford, Oxford, UK; 14Karolinska Institutet, Stockholm,
Sweden; 15The Estonian Genome Center, University of Tartu, Tartu, Estonia; 16Centre for Integrated Genomic Medical Research, Manchester Academic Health Sciences Centre,
University of Manchester, Manchester, UK; 17Ontario Institute for Cancer Research and Samuel Lunenfeld Research Institute, Toronto, ON, Canada; 18Wellcome Trust Sanger
Institute, Hinxton, UK; 19University of Helsinki, Helsinki, Finland; 20The Broad Institute of MIT and Harvard, Cambridge, MA, USA; 21National Institute for Health and Welfare,
Helsinki, Finland; 22Erasmus Medical Center, Department of Pathology, Josephine Nefkens Institute, Rotterdam, The Netherlands; 23Center for Human and Clinical Genetics,
Leiden University Medical Center, Leiden, The Netherlands; 24Center for Medical Systems Biology, Leiden, The Netherlands; 25University of Manchester, Manchester, UK;
26Medical University of Graz, Graz, Austria
*Correspondence: Dr JR Harris, Department of Genes and Environment, Division of Epidemiology, The Norwegian Institute of Public Health, Post Box 4404 Nydalen, N-0403
Oslo, Norway. E-mail: Jennifer.harris@fhi.no
European Journal of Human Genetics (2012) 20, 1105–1111
& 2012 Macmillan Publishers Limited All rights reserved 1018-4813/12
www.nature.com/ejhg
future uses of specimens and data cannot be fully anticipated
when a biobank is first established. This presents a number of major
scientific, logistic, ethico-legal, and political challenges,2 and has
important implications for the design, operation, and utilization
of biobanks.
Optimizing our ability to harness the full potential of human
biobanks for the betterment of global human health requires the
support of exploratory approaches and research infrastructures that
do not fit traditional models of hypothesis-driven research. The shift
to highly parallel investigational approaches and tools is already
underway. It requires coordination and cooperation between a diversity
of stakeholders, including policy makers and funders. Under this new
model, funding for research data, biological samples, and the infra-
structures needed to maximize their scientific utility is viewed as an
investment that will benefit the public. This is illustrated by the recent
joint statement of purpose issued by seventeen major funders of
health research, which endorses sharing data to improve public health.3
Although we outline an ambitious agenda, considerable momentum
has already been generated as illustrated by the diverse types of
international activities listed in Table 1. Importantly, the development
of biobanking resources and infrastructures, as proposed herein,
should not be viewed as competing against or replacing hypothesis-
driven research, but rather as essential tools that facilitate and support
such research.
The vision we articulate requires harmonization with the goal of
interoperability. The science of biobanking, its management, and the
political and social considerations that affect its sustainability are no
less important. Below, we address harmonization, scientific considera-
tions, ethical, legal and societal implications (ELSI), and sustainability
in detail, as a basis for further discussion.
HARMONIZATION
Harmonization of biobanking operational procedures and best
practices is an essential element that enables biobanks to exchange
and pool data and samples. This so-called interoperability is the foun-
dation of successful global biobanking. Rather than demanding com-
plete uniformity among biobanks, harmonization is a more flexible
approach aimed at ensuring the effective interchange of valid
information and samples.4,5 One critical task of the harmonization
process is to articulate those situations in which true standardization
is required. Standardization implies that precisely the same protocols/
standard operating procedures (SOPs) are used by all biobanks. For
example, if data are to be passed between biobank databases then
there needs to be agreement on standard ontologies and exchange
formats. Likewise, comparison of high-throughput-technology-derived
data requires that platforms and operational details be identical.
Harmonization is context-specific and pertains to the compatibility of
methodologies and approaches to facilitate synergistic work. It thereby
relates to the critical areas of generating, sharing, pooling, and analyz-
ing data and biological samples to allow combining resources and
comparing results obtained from different biobanks. Harmonization
encompasses enabling technologies and procedures for phenotype
characterization, sample handling, in vitro assays, computational biology
analytical tools and algorithms, data-coding and electronic-
communication protocols that enable biobanks to network together
within compatible ethico-legal frameworks.
In recognition of the necessity to synchronize efforts and build
upon previous achievements, a host of consortia-based initiatives,
project teams and agencies (Table 1) have been working to optimize
the establishment, operation, and use of interoperative biobank
resources globally as demonstrated by the Public Population Project
in Genomics and Society.6 Toward this end, best practices for
biobanking have been developed by several organizations and
groups.7–9 The fundamental principles guiding these efforts include
transparency, complementarity, and the sharing of relevant knowledge
and tools to enable cutting-edge and translational science for the
benefit of all. Harmonization initiatives have brought together
individuals with diverse expertise. On the basis of consensus, they
have developed standards,10,11 tools, technologies, and resources,
which are widely available to the biobanking community today.
Indeed, the science of biobanking has emerged as a field in its own
right, providing an ever-growing armamentarium of tools, information,
compatible bioinformatics, and SOPs. However, progress in unravel-
ing the complexities of disease etiology and developing successful
treatments will require a far greater degree of knowledge and data
integration than currently exists. Thus, how we structure and
harmonize our biobanks today will have important impact on the
future of biomedicine.
Not all biobanks have the same purpose or design. A typology of
biobanks includes: (1) residual specimens collected during routine
clinical care for therapeutic or diagnostic purposes, including collec-
tions of tumor samples with associated histopathologic, demographic,
clinical, and outcome data; (2) specimens collected during clinical
trials; (3) specimens collected as part of specific research projects; and
(4) specimens collected as part of population-based biobanks, which
often contain longitudinal components. These diverse types of
biobanks have different roles in the generation and translation of
knowledge into public health and clinical medicine, and technological
plus conceptual evolution may make it impossible or undesirable to
harmonize completely their practices, policies, and operations. None-
theless, some baseline level of harmonization should be fostered for
two main reasons. First, harmonization increases the quantity of
usable data and numbers of biospecimens to achieve levels of
statistical power necessary to detect effects underlying complex
disease etiology.12–15 Second, translational science will rely on
fundamental biological data to (re)classify human disease on the
basis of causality and to identify relevant drug targets and
biomarkers.16 Effective planning of studies will use targeted
investigations of specific groups classified on their individual,
detailed biological – as well as socio-cultural – profiles. Such
designs will enrich our analytical repertoire and may help overcome
some of the historical boundaries between clinical and nonclinical
research. Accordingly, our ability to correlate data and biospecimens
from different biobanks will be pivotal to accelerating the pace of
translational research. A meta-model to describe information about a
biobank is already under construction as a first-step data sharing
among biobanks that exhibit tremendous heterogeneities. This work
is being conducted internationally to help harmonize the national
biobanks participating in the Biobanking and Biomolecular Resources
Research Infrastructures Initiative (BBMRI).17 Information about the
participating biobanks is captured by a common set of attributes
(minimum data set) designed to adopt different kinds of collections.
The latest interoperability and semantic web technologies can be used
for building resource description frameworks for data and services
providing flexible frameworks that can be used in different data-
sharing scenarios.
Figure 1 depicts three major types of biobanks and their niches in
health-care research relative to population disease development.
Modern research strategies should be able to draw on samples and
data derived from these biobank categories to capture the full range of
biological variance associated with phenotypes ranging from
pre-disease states through response to treatment.
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Table 1 Examples of organizations, initiatives, and resources supporting the development of harmonized platforms for biobanks and biobank-
based science
Entity Description and web link
Regional and international organizations
ESBB The European, Middle Eastern & African Society for Biopreservation & Biobanking, a regional chapter of ISBER, aims to advance the field of biobanking
in support of research related to healthcare, education, and the environment. (http://www.esbb.org/)
FIBO The Forum for International Biobanking Organizations aims to improve biomedical research by enhancing interactions between organizations involved in
human biobanking at a global level. (http://www.isber.org/Partnerships/fibo.cfm)
IARC The International Agency for Research on Cancer coordinates and conducts research on the cause of human cancer and the mechanisms of
carcinogenesis, and develops scientific strategies for cancer prevention and control. (http:www.iarc.fr)




The Marble Arch Working Group aims to harmonize approaches in regional and national biobanks and address critical issues in managing a modern
human specimen biobank. (http://www.oncoreuk.org)
OECD The Organization for Economic Co-operation and Development is an international organization helping governments tackle the economic, social, and
governance challenges of a globalized economy. (http://www.oecd.org)
P3G The Public Population Project in Genomics is an international consortium with members in 40 countries. It aims to lead, catalyze, and coordinate
international efforts and expertise, so as to optimize the use of studies, biobanks, research databases, and other similar health and social research
infrastructures. (http://www.p3g.org)
Science and infrastructure initiatives




The Biomarkers Consortium is a public–private biomedical research partnership that endeavors to develop, validate, and qualify biological markers
(biomarkers) to speed the development of medicines and therapies for detection, prevention, diagnosis, and treatment of disease and improve patient
care. (http://www.biomarkersconsortium.org/)
BioSHaRE-EU The BioSHaRE-EU project aims to achieve solutions for researchers to use pooled data from different cohort and biobank studies.
(http://www.bioshare.eu)
caBIG The Cancer Biomedical Informatics Grid aims to develop a collaborative information network that accelerates the discovery of new approaches for the
detection, diagnosis, treatment, and prevention of cancer. (https://cabig.nci.nih.gov/)
caHUB The Cancer Human Biobank aims to advance cancer research and treatment through development of a national center for biospecimen science and
standards. (http://cahub.cancer.gov/)
CPT The Canadian Partnership for Tomorrow Project aims to establish a platform to facilitate research into the interplay between genes, lifestyle and
environment, and subsequent impact on risk of cancer and other chronic diseases in Canadian adults. (http://www.partnershipagainstcancer.ca)
EATRIS The European Advanced Translational Research Infrastructure in medicine aims at translating research findings into improved diagnosis, disease
prevention, and treatment. (http://www.eatris.eu/)
ECRIN The European Clinical Research Infrastructure project aims to implement a research infrastructure accessible to all clinical researchers in the EU
member and associated states.(http://www.ecrin.org)
Gen2Phen The Human Genome Variation Genotype-to-Phenotype database aims to unify human and model organism genetic variation databases.
(http:www.gen2phen.org)
GraPH-Int The Genome-based Research and Population Health International Network is a global collaboration of individuals and organizations with an interest in
public health genomics. (http://www.graphint.org)
ICGC The International Cancer Genome Consortium aims to obtain a comprehensive description of genomic, transcriptomic, and epigenomic changes in 50








The Human Variome Project is a global initiative to collect and curate all human genetic variation affecting human health. (http://www.humanvar-
iomeproject.org/)
HuGENet The Human Genome Epidemiology Network is a global collaboration of individuals and organizations committed to the assessment of the impact of
human genome variation on population health. (http://www.hugenet.org.uk)
PHGEN II PHGEN II builds on the experiences of PHGEN I (Public Health Genomics European Network), which was a networking exercise to develop a common
understanding of Public Health Genomics between all stakeholders in Europe. (http://www.phgen.eu/typo3/index.php?id=103)
PHOEBE The Promoting Harmonization for Epidemiological Biobanks project aims to establish a collaborative research network to identify and explore key issues
related to the use of population-based biobanks and longitudinal cohort studies. (http://www.phoebe-eu.org)
UKDBN The UK DNA Banking Network aims to support genetic epidemiology in the translation of the human genome sequence into health benefits.
(http://www.dna-network.ac.uk)
OECI-Tubafrost The European Human Tumor Frozen Tissue Bank collects information on human material ie frozen tumor tissue specimens, pathology blocks, blood
samples in different forms, cell lines, and Tissue Micro Arrays. (http://www.tubafrost.org)
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SCIENTIFIC CONSIDERATIONS
To ensure scientific excellence while optimally leveraging the potential
of biobanks, the scientific frameworks within which biobanks operate
will need to keep advancing in several critical areas, including: (1)
networking of multidisciplinary professionals; (2) development of
comprehensive inventories, including listing of extant biobanks, their
holdings, and access procedures; (3) establishment of standardized
data-collection protocols governed by appropriate quality manage-
ment systems; (4) continued innovation that leads to improved
technologies for preservation of biospecimens and pre-analytical
processes, (5) progress in information infrastructure to facilitate data
sharing and pooling, including new technical solutions for data
management and analysis, as well as for the protection of participant
privacy and data confidentiality; and (6) harmonization of quality
management systems to ensure consistency of materials.
The science of biobanking itself is as important to develop and
fund as the science that uses biobanks. Because the science of
biobanking is very closely linked to the development of an enabling
infrastructure, it requires scientists to work more closely with each
other and with funders than has historically been the norm in
biomedical science. In this, biobanking resembles more the situation
typical for large-scale physics, which is characterized by close
collaborative, pre-competitive relationships among workers in the
field to construct, develop, and maintain the necessary research
infrastructures while embracing healthy competition in the under-
taking of both hypothesis-based and free research using these
infrastructures. Developing this kind of culture and spirit will be
essential for the success of large, cross-institutional biobanking efforts.
Meeting these needs will require stable funding and new mechan-
isms to support the coordination of infrastructure programs
internationally.18 Other elements essential to the successful
nurturing of a vibrant research community include frequent
interchanges that will seed and foster relationships among scientists
in the field, non-risk-averse early funding for small exploratory
research projects, and the maintenance of registries of relevant
professionals. Several of the major initiatives listed in Table 1 are
already helping to meet these needs. However, they currently lack the
kind of stable funding required not only for the activities listed above,
but – importantly – also for the development of networking among
biobanking professionals that can lead to the development of multi-
disciplinary research projects.
Training of the next generation of biobanking professionals is a
critical aspect that requires focused attention and investment, as is the
establishment of communication and publishing conduits for sharing
resources and results. Specific attention will also need to be paid to
career development and advancement aspects of biobanking scientists
in an effort to correct the current perception of the profession as mere
infrastructure providers. Likewise, the field itself still needs to build
reputation and recognition as a scientific discipline as opposed to an
‘ancillary service’.
ETHICAL, SOCIETAL, AND POLICY CONSIDERATIONS
No less important than harmonization of specimens and data is the
promotion and implementation of shared ethical principles and
procedures as they relate to biobanking. Although the last decade
has seen the emergence of principles reflecting shared ethical pri-
nciples that foster international scientific collaborations,19 the
concepts of altruism, of solidarity,20,21 or of databases as global
‘public goods’22,23 to promote data sharing,24 are still evolving.25
Building trust, so that individuals will continue to donate to biobanks
Table 1 (Continued )
Entity Description and web link
Resource tools and databases
dbGap The Database of Genotypes and Phenotypes is a public repository for individual-level phenotype, exposure, genotype and sequence data and the
associations between them. (http://www.ncbi.nlm.nih.gov/gap)
DataSHaPER The Data Schema and Harmonization Platform for Epidemiological Research is a tool aiming to facilitate the harmonization of studies.
(http://www.datashaper.org)
DataSHIELD The Data Aggregation Through Anonymous Summary-statistics from Harmonized Individual-levEL Databases provides a novel approach to data synthesis,
based on parallel processing and distributed computing. (http://www.p3gobservatory.org)




ESPRESSO (The Estimating Sample-size and Power in R by Exploring Simulated Study Outcomes) is a new ‘R’-based program for simulation-based
power calculation that can be used to estimate realistic sample-size requirements for case–control and cohort studies in population genomics where
analysis focuses on either direct genetic or environmental effects or interactions. (http://www.p3gobservatory.org)
HapMap The International HapMap Project is a joint effort to identify and catalog genetic similarities and differences between human beings.
(http://www.hapmap.org)
HUMGEN The HUMGEN International Database is a resource concerning ethical, legal, and social issues in human genetics.
(http://www.humgen.org/int/)
PhenX The Consensus measures for Phenotypes and eXposures project aims to contribute to the integration of genetics and epidemiologic research.
(http://www.phenx.org)
OBIBA The Open Source Software for Biobanks is a collaborative international project whose mission is to build high-quality open source software for biobanks.
(http://www.obiba.org)
OBO The Open Biological and Biomedical Ontologies project aims to establish a set of principles for ontology development with the goal of creating a suite of
orthogonal interoperable reference ontologies in the biomedical domain. (http://www.obofoundry.org/)
P3G Catalogs The P3G catalogs provide access to information about large population-based biobanks. (http://www.p3gobservatory.org)
SPIDIA The SPIDIA (Standardization and improvement of generic preanalytical tools and procedures for in vitro diagnostics) project aims to provide the scientific
basis for European standards and norms for sample preanalytics. (http://www.spidia.eu)
STORE The STORE (Sustaining access to tissues and data from radiobiological experiments) project aims to create a platform for the storage and dissemination
of both data and biological materials from past, present, and future radiobiological research. (http://fp7store.de/pages/home.php?lang¼EN)
TISS.EU The Tiss.EU project aims to analyze the impact of current EU legislation and guidelines on biomedical research. (http://www.tisseu.uni-hannover.de/)
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for the benefit of all, is essential to ensure the advance of biomedical
research. Society must recognize its role in this process and take steps
to protect research participants against the possible misuse of their
information. This will require building governance mechanisms that
operate at a meta-level to enable accountable and responsible
research. Furthermore, we must develop approaches to foster trust
related to specific contexts with which biobanks will interface,
including, for example, industry and health care.
The authors strongly advocate that the necessary procedural
mechanisms for privacy protection and the use of IT software and
biostatistical solutions to facilitate secure use26 and transfer of data
across borders27 be adopted and implemented more broadly by
the global biobanking community as a matter of high priority.
In addition, it will be important to build the mutual trust that is
required for the delegation of ethics review across jurisdictions, where
such delegation is feasible and appropriate.28 The use of researcher
authentication techniques may provide additional protections and
can be expected to develop gradually. For example, the Open
Researcher and Contributor ID initiative enables institutionally
verifiable and reliable disambiguation of one author from another.29
The mandatory deposition of certain data into the public domain and
publication policies of journals enforcing transparency on these issues
constitute important steps in these directions.30
In order to build a global infrastructure involving high-quality
specimens and data collections to support a broad array of scientific
projects, a highly supportive political environment is also critical.
Strengthening relationships with governments, ministries, industry,
and the general public will be crucial to create and maintain such an
environment. Developing a global biobanking infrastructure is
expensive and relies on the willingness of individual participants to
act as ‘global citizens’ – or as ‘citizen scientists’31 – by providing their
specimens and data for the greater good of science and progress in
individual and public health. Consideration should be given to
working closely with agencies that communicate effectively the
importance of science to educate the media and the general public.
It is the responsibility of stakeholders to react sensitively and respon-
sively to public and political perceptions and to maintain transparent,
accountable information on their activities.7 In particular, general
information on projects of researchers who have used the biobanks
should be publically available.32
An important element of infrastructural development involves
substantial investment in ensuring ethical, effective, and equitable
access to banked data and samples. This often involves overlapping,
but sometimes competing interests of biobank scientists and managers,
secondary users of the biobank, study participants, funders, ethico-legal
experts, and the public at large. Such a multiplicity of stakeholders
means that some issues can only be resolved at the highest level, with
agreement on policy at an international level after significant stake-
holder input. Solutions include recognizing that data/samples funded
from public funds are a shared resource for the promotion of scientific
research for the public good, with adequate funding/cooperation and
recognition of the contributions, which make these resources available,
and with the provision of sanctions for those that misuse biobanks
and/or specimens and data.24 To this end, the biobanking community
and funders must work together with policy makers on regional,
national, and international levels to provide legal and ethical
frameworks or, at minimum, reciprocal ‘safe harbor’ recognition to
encourage the use and sharing of data, samples, and knowledge. This
will require international consensus guidance and collaboration to
ensure equitable approaches to the governance of privacy and access
and the development of training programmes for members of ethics
review boards and other data regulatory bodies. Current challenges are
often related to the application of existing regulations and policies that
were developed for patient safety and protection in interventional
clinical trials involving new, potentially harmful drugs, devices, or
psychological interventions; we argue that these norms are ill-suited for
application to observational studies such as longitudinal population
studies, with minimal risks (related primarily to data protection).
Obviously, there must be sufficient investment in the infrastructure,
personnel, and processes that enable data management, archiving and
release under a pragmatic, simplified, streamlined ethics review.
SUSTAINABILITY
Long-term sustainability is a major challenge for biobanking.
A number of considerations are critical to keeping biobanks and
the research they support active and dynamic. The need for long-term
Figure 1. Overview of the three major types of biobanks and their niches in health-care research relative to population disease development and their
possible future cooperative role.
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investments into biological resources is clearly evident when long-
itudinal data are needed. Prospective collections of data and samples
from asymptomatic individuals will allow future identification of
premorbid and subclinical periods of disease development and will
identify prognostic and diagnostic biomarkers and drug targets.13,33,34
Treatment follow-up studies require sampling and data collection
over many years before substantive analysis can be per-
formed. As molecular approaches to health and translational
medicine are still in nascent stages, the value of already collected
data will continue to grow as new knowledge and methodologies are
applied to biobanks. Thus, preservation of today’s biobanks is critical
for realising the science and medicine of tomorrow.
Most conventional grant mechanisms with limited periods of
funding are not sufficient for such sustainability.18 Alternative appro-
aches to providing long-term support, such as the NIH contract model
that has supported the Framingham Study, a distinguished successful
biobanking initiative (nota bene, since long before the term
‘biobanking’ was coined), must be developed and expanded. It may
well be that the answer will lie in the use of a combination of
approaches that includes long-term commitments from public and
governmental sources27 (eg, the Estonian Human Genes Act (y27)) for
functions related to the collection, maintainance, and storage of
samples and information,35 as well as support from private industry.36
Embedding biobanks in health-care systems would help ensure
reliable long-term funding and establish biobanks as a key component
of the public health infrastructure. Both the long-term scientific
benefits to be accrued from biobanking, and the personal health-care-
related benefits that individuals may gain from having objective
health-related information stored in biobanks, suggest that at least
some types of biobanks may become nested within the health-care
system.37 Indeed this trend is already evident in many nations as
reflected by the ever-growing number of national hubs associated
with the BBMRI.38,39 If we want to ensure that the environment is
right to support such nesting, it is critical that biobank operators,
biobanking scientists, and science funders work hand in hand with
policy makers and health-care strategists at all levels to ensure that the
development of governance systems and regulatory frameworks,
mechanisms for quality management, and systems for data storage,
transfer, and integration are all harmonized and aligned to meet
current and future needs. If done properly, such a systematic
integration may be the essential foundation for future contributions
that biobanks can make to human health. Thus, the design of
approaches for data sharing across the spectrum of biobanks should
dovetail with national health information systems to ensure that these
systems are capable of interfacing (in an appropriately controlled
manner) with the IT systems that hold the bulk of the detailed
information in biobanks.
Obviously, funding is conditional on the level of ongoing benefit
produced. Thus it is critical that biobanks are evaluated on an
ongoing basis using well-defined metrics.40 This implies the urgent
need to develop more formalized systems to objectively assess the
value of biobanks or biobank networks over time. No such moni-
toring system exists yet, though some ideas for measuring a
‘Bio-Resource Impact Factor’ (BRIF) are being designed and
piloted.41 It will be necessary to record simultaneously the impact of
biobanks as infrastructures supporting research and the scientific and
operational contributions made by the ‘biobank researchers’
(principal investigators, managers, bioinformaticians so on). This
will be assisted by the development of systems that track the history of
biobank collections and their applications using digital IDs for
biobanks and researchers, and by a growing emphasis on publishing
infrastructure data, as well as discoveries made as a result of accessing
them. This, in turn, requires continued improvements in the
underlying controlled vocabularies, databases, search systems, and
guidelines addressing the ethical, legal, and social issues related to
biobanks. Best practices for evaluating biobanks should
be established42 and routinely updated. Likewise, criteria should be
established to terminate biobanks, which fail to meet the established
requirements and metrics.7 In addition to quantitative metrics for
assessing the utility of biobanks, it is essential to also consider the less
tangible, qualitative impact biobanks may have in fostering scientific
advances43,44 The development and use of such metrics also serve
another purpose that may affect sustainability needs: such metrics
help to incentivize and justify the field by providing objective criteria
for unambiguously qualifying scientific contributions by engaged
investigators.
CONCLUSION
Biobanking has the potential to be the most powerful single platform
for health innovation and knowledge generation, provided that it is
adequately resourced and networked. Maximizing the use, productiv-
ity, and value of biobanks worldwide will depend on a transition of
the way in which biobanking is perceived and conducted. Harmoni-
zation across biobanks is crucial in order to make investigations more
robust, more targeted, and more economical. Building on funda-
mental principles that emphasize synergy of effort, openness, and
resource sharing for the benefit of all, international biobanking efforts
have already begun to lay the groundwork for such harmonization.
To realize fully the major public health benefits from the current
patchwork of biobanking efforts, a coordinated strategy is required
that engages the diverse stakeholders and proceeds through consensus
building. We have articulated a vision and outlined a number of
strategies for building the scientific, social, and political framework
for continued progress. The key considerations underpinning the
successful implementation of a road map to develop biobanking
globally for health are summarized in Table 2. Drawing from the
experience of an impressive number of harmonization initiatives in
the field, we propose working to establish an international biobanking
infrastructure and community. The collective output of these efforts
includes guidance for the design and management of biobanks, for
Table 2 Summary of key considerations underpinning a roadmap in global biobanking for health
1. Foster biobank interoperability through the development and maintenance of enabling technologies, procedures, networks, and compatible ethico-legal frameworks.
2. Ensure optimal strategic development, access, and utilization of biobank infrastructures across all stakeholders.
3. Promote legal systems that enable international biobanking and the safely regulated sharing of specimens and data.
4. Support the recognition of the scientific contributions of biobankers.
5. Encourage the development of formal systems for the evaluation of the impact of biobanks.
6. Enhance understanding of biobanking by the media, the general public, policymakers, and health-care strategists.
7. Build trust and respect for both open communication and a shared commitment to advance science for the improvement of human health.
8. Develop sustainability through stable funding and the embedding of biobanks in health-care systems.
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the development of SOPs for sample handling within a Quality
Management System, cataloging and comparing data, and for
coordinating development of compatible bioinformatics and
ethico-legal frameworks. In addition to fostering biobank interoper-
ability, with regard to the collection and exchange of data and
samples, it is critical to form strategic alliances between governmental
bodies, funding agencies, public and private science enterprises, and
other stakeholders. The foundations of modern biobanking science
have been laid. The challenges we describe must be met, if we are to
realize, mobilize, and sustain the promise of major individual and
public health benefits through the application of biobanking to
biomedical research.
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